<?xml version="1.0" encoding="UTF-8"?>
<p id="para0030">Type I interferons designate a cluster of antiviral cytokines consisting of the omnipresent α and β subtypes, along with the ω, ε and κ subtypes, inducing large numbers of proteins that can undermine viral replication in host cells 
 <xref rid="bib0094" ref-type="bibr">[94]</xref>. Former researches have revealed that IFN-β was superior against SARS-CoV in comparison with IFN-α 
 <xref rid="bib0095" ref-type="bibr">[95]</xref>. As for the clinical trial of type I interferons, in China, therapy guidelines for COVID-19 recommend the management of 5 million U of IFN-α via vapor inhalation in patients twice daily with ribavirin as combined therapy 
 <xref rid="bib0096" ref-type="bibr">[96]</xref>. In the detailed study of Sallard et al., they reported that IFN-β1 might constitute a safe and easy to upscale therapy against COVID-19 in the early stages of the disease. Besides, 
 <italic>in vitro</italic> data indicated that this virus might be significantly more sensitive to IFN-I than other CoVs 
 <xref rid="bib0080" ref-type="bibr">[80]</xref>.
 <list list-type="simple" id="celist0003">
  <list-item id="celistitem0003">
   <label>(III)</label>
   <p id="para0031">Protease inhibitors</p>
  </list-item>
 </list>
</p>
